IO Combinations 360° convenes industry and academic leaders to address scientific, clinical and business developments in IO combination strategies to fight a wider range of cancers.

IO Combinations 360° provides the most up-to-date research, data and progress on combination developments to help IO stakeholders:

- Be at the forefront of the most relevant research and developments for IO combinations from key leadership who are at the pulse of cancer immunotherapy
- Foster collaboration amongst others working in all aspects of cancer immunotherapy by rounding up all stakeholders under one roof
- Receive the latest pre-clinical, translational and clinical data from academia and industry
- Better understand what assets are available for potential combinations that may be able to give patients more treatment options
- Create and prioritize combination strategies targeted toward specific tumor types
- Get key investor and analyst evaluations and insights on the IO combination landscape
- Learn about biomarker advancements, neoantigen approaches and more
- Obtain coverage on a wide range of emerging technologies